News
-
-
-
COMMUNIQUÉ DE PRESSE
Half-year financial statements close with balanced EBITDA, Trauma with positive EBITDA
aap Implantate AG reports balanced EBITDA with positive results in trauma business for the first half of 2024. Sales increased by 10% to EUR 6.4 million, driven by EMEA region growth. Key figures include stable gross margin and improved EBITDA -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Amendment of the terms and conditions of the bond completed; Bondholders can convert bonds into shares
aap Implantate AG completes amendment of bond terms allowing bondholders to convert bonds into shares. Conversion period until May 29, 2024. For more information, visit https://www.aap.de/investoren/wandelschuldverschreibung -
